Clinical Trial

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2026 (before its estimated April 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-04-10; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2020-11-17
Trial Details
NCT Number NCT04342910
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Gastric Cancer
Enrollment 550 participants
Start Date 2020-09-21
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-20